Dexmethylphenidate - Revision history

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:06Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

MDElliottMD: Sweep: "indications" -> "problems" sitewide terminology update (preserves MedTemplate param name)

2026-05-19T01:37:42Z

Sweep: "indications" -> "problems" sitewide terminology update (preserves MedTemplate param name)

MDElliottMD: Recategorize: Stimulants -> Psychostimulants

2026-05-17T10:50:37Z

Recategorize: Stimulants -> Psychostimulants

← Older revision		Revision as of 10:50, 17 May 2026
Line 180:		Line 180:
	<span></span><discuss slug="personal-experience" />		<span></span><discuss slug="personal-experience" />

	[[Category:~~Stimulants~~]]		[[Category:Psychostimulants]]
	[[Category:Methylphenidates (Phenidates)]]		[[Category:Methylphenidates (Phenidates)]]

MDElliottMD: Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

2026-05-17T10:44:50Z

Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

← Older revision		Revision as of 10:44, 17 May 2026
Line 180:		Line 180:
	<span></span><discuss slug="personal-experience" />		<span></span><discuss slug="personal-experience" />

	[[Category:Stimulants ~~& Wake-Promoting Agents~~]]		[[Category:Stimulants]]
	[[Category:Methylphenidates (Phenidates)]]		[[Category:Methylphenidates (Phenidates)]]

Maintenance script: Terminology: medicine → med (shorter form per user preference)

2026-05-16T02:42:46Z

Terminology: medicine → med (shorter form per user preference)

Maintenance script: Terminology sweep (site-wide): drug/medication → medicine

2026-05-16T02:30:55Z

Terminology sweep (site-wide): drug/medication → medicine

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:06:55Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:06, 14 May 2026
Line 179:		Line 179:
	''The following are personal accounts and not medical advice.''		''The following are personal accounts and not medical advice.''
	<span></span><discuss slug="personal-experience" />		<span></span><discuss slug="personal-experience" />

			[[Category:Stimulants & Wake-Promoting Agents]]
			[[Category:Methylphenidates (Phenidates)]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:30:48Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:30, 14 May 2026
Line 72:		Line 72:

	Like racemic methylphenidate, '''few CYP-mediated interactions''' due to CES1-dominated metabolism.		Like racemic methylphenidate, '''few CYP-mediated interactions''' due to CES1-dominated metabolism.
			<pharmaInteractions/>
	\| pregnancy_details = Category C. Crosses the placenta. Reproductive data limited and largely extrapolated from racemic methylphenidate; overall not clearly teratogenic but cohort studies suggest a small increase in cardiac malformations. Third-trimester exposure can produce transient neonatal withdrawal. Risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in low amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring.		\| pregnancy_details = Category C. Crosses the placenta. Reproductive data limited and largely extrapolated from racemic methylphenidate; overall not clearly teratogenic but cohort studies suggest a small increase in cardiac malformations. Third-trimester exposure can produce transient neonatal withdrawal. Risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in low amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring.
	\| monitoring = * Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use		\| monitoring = * Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:30Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 61:		Line 61:
	* <effect ref="seizure">Caution in epilepsy.</effect>		* <effect ref="seizure">Caution in epilepsy.</effect>
	* <effect ref="withdrawal">Fatigue, rebound hyperactivity, dysphoria on dose offset.</effect>		* <effect ref="withdrawal">Fatigue, rebound hyperactivity, dysphoria on dose offset.</effect>
	~~\| contraindications = * Hypersensitivity to dexmethylphenidate or methylphenidate~~
	* Concurrent MAOI use, or within 14 days of MAOI discontinuation
	* Symptomatic cardiovascular disease, advanced atherosclerosis, moderate–severe hypertension, recent MI
	* Hyperthyroidism
	* Glaucoma
	* Pheochromocytoma
	* Severe anxiety, tension, or agitation
	* '''Relative:''' Tourette syndrome / tic disorders, history of substance use disorder, bipolar disorder, psychotic disorders, structural cardiac abnormalities
	\| interactions = * '''MAOIs''' — hypertensive crisis risk; contraindicated within 14 days		\| interactions = * '''MAOIs''' — hypertensive crisis risk; contraindicated within 14 days
	* '''Tricyclic antidepressants''' — possible elevation of TCA levels; additive cardiovascular effects		* '''Tricyclic antidepressants''' — possible elevation of TCA levels; additive cardiovascular effects

MDElliottMD: Migrated 52 effect tag(s) to global ref=

2026-05-13T00:51:17Z

Migrated 52 effect tag(s) to global ref=

Show changes

← Older revision		Revision as of 01:37, 19 May 2026
Line 14:		Line 14:
	\| pregnancy = Category C		\| pregnancy = Category C
	\| legal = Schedule II		\| legal = Schedule II
	\| intro = '''Dexmethylphenidate''' — marketed as '''Focalin''' and '''Focalin XR''' — is the isolated d-threo enantiomer of [[Methylphenidate\|methylphenidate]]. Racemic methylphenidate contains both d- and l-threo enantiomers in equal amounts, but essentially all pharmacologic activity resides in the d-isomer; the l-isomer is rapidly cleared on first-pass and contributes little beyond a possible minor role in peripheral side effects. By delivering only the active enantiomer, Focalin achieves equivalent therapeutic effect at approximately half the milligram dose of racemic methylphenidate, with some patients reporting a cleaner subjective profile (less jitteriness, more focused effect). Its clinical ~~indications~~, mechanism, contraindications, and adverse-effect profile are otherwise nearly identical to racemic methylphenidate.		\| intro = '''Dexmethylphenidate''' — marketed as '''Focalin''' and '''Focalin XR''' — is the isolated d-threo enantiomer of [[Methylphenidate\|methylphenidate]]. Racemic methylphenidate contains both d- and l-threo enantiomers in equal amounts, but essentially all pharmacologic activity resides in the d-isomer; the l-isomer is rapidly cleared on first-pass and contributes little beyond a possible minor role in peripheral side effects. By delivering only the active enantiomer, Focalin achieves equivalent therapeutic effect at approximately half the milligram dose of racemic methylphenidate, with some patients reporting a cleaner subjective profile (less jitteriness, more focused effect). Its clinical problems, mechanism, contraindications, and adverse-effect profile are otherwise nearly identical to racemic methylphenidate.
	\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated med interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.		\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated med interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.
	\| pharmacodynamics = Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.		\| pharmacodynamics = Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.
	\| indications = * Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)		\| indications = * Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)
	* Off-label: same off-label uses as racemic methylphenidate (treatment-resistant depression augmentation, cancer/HIV/MS fatigue)		* Off-label: same off-label uses as racemic methylphenidate (treatment-resistant depression augmentation, cancer/HIV/MS fatigue)
	* Not FDA-approved for narcolepsy (use racemic methylphenidate or an amphetamine for that ~~indication~~)		* Not FDA-approved for narcolepsy (use racemic methylphenidate or an amphetamine for that problem)
	\| dosing = '''Focalin IR:''' Start 2.5 mg PO twice daily (separate doses by at least 4 h). Titrate by 2.5–5 mg/week. Max 20 mg/day (adults and children).		\| dosing = '''Focalin IR:''' Start 2.5 mg PO twice daily (separate doses by at least 4 h). Titrate by 2.5–5 mg/week. Max 20 mg/day (adults and children).
	'''Focalin XR:''' Start 5 mg PO once daily AM (children), 10 mg PO once daily AM (adults). Titrate weekly. Max 30 mg/day (children); 40 mg/day (adults).		'''Focalin XR:''' Start 5 mg PO once daily AM (children), 10 mg PO once daily AM (adults). Titrate weekly. Max 30 mg/day (children); 40 mg/day (adults).
Line 93:		Line 93:
	}}<h2 id="Pharmacokinetics">Pharmacokinetics</h2><span></span>		}}<h2 id="Pharmacokinetics">Pharmacokinetics</h2><span></span>
	'''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated med interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.<h2 id="Pharmacodynamics">Pharmacodynamics</h2>		'''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated med interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.<h2 id="Pharmacodynamics">Pharmacodynamics</h2>
	Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.<h2 id="~~Indications~~">~~Indications~~</h2>		Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.<h2 id="Problems">Problems</h2>
	*Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)		*Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)
	*Off-label: same off-label uses as racemic methylphenidate (treatment-resistant depression augmentation, cancer/HIV/MS fatigue)		*Off-label: same off-label uses as racemic methylphenidate (treatment-resistant depression augmentation, cancer/HIV/MS fatigue)
	*Not FDA-approved for narcolepsy (use racemic methylphenidate or an amphetamine for that ~~indication~~)<h2 id="Dosing">Dosing and titration</h2>		*Not FDA-approved for narcolepsy (use racemic methylphenidate or an amphetamine for that problem)<h2 id="Dosing">Dosing and titration</h2>
	<span></span>		<span></span>

← Older revision		Revision as of 02:42, 16 May 2026
Line 15:		Line 15:
	\| legal = Schedule II		\| legal = Schedule II
	\| intro = '''Dexmethylphenidate''' — marketed as '''Focalin''' and '''Focalin XR''' — is the isolated d-threo enantiomer of [[Methylphenidate\|methylphenidate]]. Racemic methylphenidate contains both d- and l-threo enantiomers in equal amounts, but essentially all pharmacologic activity resides in the d-isomer; the l-isomer is rapidly cleared on first-pass and contributes little beyond a possible minor role in peripheral side effects. By delivering only the active enantiomer, Focalin achieves equivalent therapeutic effect at approximately half the milligram dose of racemic methylphenidate, with some patients reporting a cleaner subjective profile (less jitteriness, more focused effect). Its clinical indications, mechanism, contraindications, and adverse-effect profile are otherwise nearly identical to racemic methylphenidate.		\| intro = '''Dexmethylphenidate''' — marketed as '''Focalin''' and '''Focalin XR''' — is the isolated d-threo enantiomer of [[Methylphenidate\|methylphenidate]]. Racemic methylphenidate contains both d- and l-threo enantiomers in equal amounts, but essentially all pharmacologic activity resides in the d-isomer; the l-isomer is rapidly cleared on first-pass and contributes little beyond a possible minor role in peripheral side effects. By delivering only the active enantiomer, Focalin achieves equivalent therapeutic effect at approximately half the milligram dose of racemic methylphenidate, with some patients reporting a cleaner subjective profile (less jitteriness, more focused effect). Its clinical indications, mechanism, contraindications, and adverse-effect profile are otherwise nearly identical to racemic methylphenidate.
	\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated ~~medicine~~ interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.		\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated med interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.
	\| pharmacodynamics = Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.		\| pharmacodynamics = Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.
	\| indications = * Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)		\| indications = * Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)
Line 78:		Line 78:
	* At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence		* At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence
	* Sleep quality and timing of last dose		* Sleep quality and timing of last dose
	* Periodically reassess continued need; consider ~~medicine~~ holidays in children		* Periodically reassess continued need; consider med holidays in children
	\| counseling = * Take in the morning (XR) or twice daily 4+ hours apart (IR); avoid late-afternoon dosing to minimize insomnia.		\| counseling = * Take in the morning (XR) or twice daily 4+ hours apart (IR); avoid late-afternoon dosing to minimize insomnia.
	* '''Focalin XR capsules:''' may be swallowed whole or opened and sprinkled on applesauce; '''do not crush or chew the beads inside.'''		* '''Focalin XR capsules:''' may be swallowed whole or opened and sprinkled on applesauce; '''do not crush or chew the beads inside.'''
Line 92:		Line 92:
	\| references =		\| references =
	}}<h2 id="Pharmacokinetics">Pharmacokinetics</h2><span></span>		}}<h2 id="Pharmacokinetics">Pharmacokinetics</h2><span></span>
	'''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated ~~medicine~~ interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.<h2 id="Pharmacodynamics">Pharmacodynamics</h2>		'''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated med interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.<h2 id="Pharmacodynamics">Pharmacodynamics</h2>
	Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.<h2 id="Indications">Indications</h2>		Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.<h2 id="Indications">Indications</h2>
	*Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)		*Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)
Line 165:		Line 165:
	*At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence		*At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence
	*Sleep quality and timing of last dose		*Sleep quality and timing of last dose
	*Periodically reassess continued need; consider ~~medicine~~ holidays in children<h2 id="Counseling">Patient counseling</h2>		*Periodically reassess continued need; consider med holidays in children<h2 id="Counseling">Patient counseling</h2>
	*Take in the morning (XR) or twice daily 4+ hours apart (IR); avoid late-afternoon dosing to minimize insomnia.		*Take in the morning (XR) or twice daily 4+ hours apart (IR); avoid late-afternoon dosing to minimize insomnia.
	*'''Focalin XR capsules:''' may be swallowed whole or opened and sprinkled on applesauce; '''do not crush or chew the beads inside.'''		*'''Focalin XR capsules:''' may be swallowed whole or opened and sprinkled on applesauce; '''do not crush or chew the beads inside.'''

← Older revision		Revision as of 02:30, 16 May 2026
Line 15:		Line 15:
	\| legal = Schedule II		\| legal = Schedule II
	\| intro = '''Dexmethylphenidate''' — marketed as '''Focalin''' and '''Focalin XR''' — is the isolated d-threo enantiomer of [[Methylphenidate\|methylphenidate]]. Racemic methylphenidate contains both d- and l-threo enantiomers in equal amounts, but essentially all pharmacologic activity resides in the d-isomer; the l-isomer is rapidly cleared on first-pass and contributes little beyond a possible minor role in peripheral side effects. By delivering only the active enantiomer, Focalin achieves equivalent therapeutic effect at approximately half the milligram dose of racemic methylphenidate, with some patients reporting a cleaner subjective profile (less jitteriness, more focused effect). Its clinical indications, mechanism, contraindications, and adverse-effect profile are otherwise nearly identical to racemic methylphenidate.		\| intro = '''Dexmethylphenidate''' — marketed as '''Focalin''' and '''Focalin XR''' — is the isolated d-threo enantiomer of [[Methylphenidate\|methylphenidate]]. Racemic methylphenidate contains both d- and l-threo enantiomers in equal amounts, but essentially all pharmacologic activity resides in the d-isomer; the l-isomer is rapidly cleared on first-pass and contributes little beyond a possible minor role in peripheral side effects. By delivering only the active enantiomer, Focalin achieves equivalent therapeutic effect at approximately half the milligram dose of racemic methylphenidate, with some patients reporting a cleaner subjective profile (less jitteriness, more focused effect). Its clinical indications, mechanism, contraindications, and adverse-effect profile are otherwise nearly identical to racemic methylphenidate.
	\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated ~~drug~~ interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.		\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated medicine interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.
	\| pharmacodynamics = Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.		\| pharmacodynamics = Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.
	\| indications = * Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)		\| indications = * Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)
Line 78:		Line 78:
	* At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence		* At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence
	* Sleep quality and timing of last dose		* Sleep quality and timing of last dose
	* Periodically reassess continued need; consider ~~drug~~ holidays in children		* Periodically reassess continued need; consider medicine holidays in children
	\| counseling = * Take in the morning (XR) or twice daily 4+ hours apart (IR); avoid late-afternoon dosing to minimize insomnia.		\| counseling = * Take in the morning (XR) or twice daily 4+ hours apart (IR); avoid late-afternoon dosing to minimize insomnia.
	* '''Focalin XR capsules:''' may be swallowed whole or opened and sprinkled on applesauce; '''do not crush or chew the beads inside.'''		* '''Focalin XR capsules:''' may be swallowed whole or opened and sprinkled on applesauce; '''do not crush or chew the beads inside.'''
Line 92:		Line 92:
	\| references =		\| references =
	}}<h2 id="Pharmacokinetics">Pharmacokinetics</h2><span></span>		}}<h2 id="Pharmacokinetics">Pharmacokinetics</h2><span></span>
	'''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated ~~drug~~ interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.<h2 id="Pharmacodynamics">Pharmacodynamics</h2>		'''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated medicine interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.<h2 id="Pharmacodynamics">Pharmacodynamics</h2>
	Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.<h2 id="Indications">Indications</h2>		Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.<h2 id="Indications">Indications</h2>
	*Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)		*Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)
Line 165:		Line 165:
	*At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence		*At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence
	*Sleep quality and timing of last dose		*Sleep quality and timing of last dose
	*Periodically reassess continued need; consider ~~drug~~ holidays in children<h2 id="Counseling">Patient counseling</h2>		*Periodically reassess continued need; consider medicine holidays in children<h2 id="Counseling">Patient counseling</h2>
	*Take in the morning (XR) or twice daily 4+ hours apart (IR); avoid late-afternoon dosing to minimize insomnia.		*Take in the morning (XR) or twice daily 4+ hours apart (IR); avoid late-afternoon dosing to minimize insomnia.
	*'''Focalin XR capsules:''' may be swallowed whole or opened and sprinkled on applesauce; '''do not crush or chew the beads inside.'''		*'''Focalin XR capsules:''' may be swallowed whole or opened and sprinkled on applesauce; '''do not crush or chew the beads inside.'''